Sierra Oncology Inc (SRRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,092 | -47,867 | -38,619 | -23,410 | -10,538 |
| Depreciation Amortization | 53 | 197 | 151 | 106 | 52 |
| Accounts payable and accrued liabilities | -1,452 | 2,246 | -184 | 376 | 1,415 |
| Other Working Capital | -1,887 | 171 | 6,157 | 252 | -121 |
| Other Operating Activity | 3,014 | 4,090 | 4,996 | 3,123 | -39 |
| Operating Cash Flow | $-11,364 | $-41,163 | $-27,499 | $-19,553 | $-9,231 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -78 | -171 | -153 | -180 | -179 |
| Other Investing Activity | 0 | 25 | 25 | 25 | 25 |
| Investing Cash Flow | $-78 | $-146 | $-128 | $-155 | $-154 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 27,445 | 211 | 194 | 120 | 96 |
| Other Financing Activity | 0 | -15 | -15 | -15 | -15 |
| Financing Cash Flow | $27,445 | $196 | $179 | $105 | $81 |
| Exchange Rate Effect | 2 | -60 | -50 | -27 | -5 |
| Beginning Cash Position | 109,207 | 150,180 | 150,180 | 150,180 | 150,180 |
| End Cash Position | 125,212 | 109,007 | 122,682 | 130,550 | 140,871 |
| Net Cash Flow | $16,005 | $-41,173 | $-27,498 | $-19,630 | $-9,309 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,364 | -41,163 | -27,499 | -19,553 | -9,231 |
| Capital Expenditure | -78 | -214 | -196 | -193 | -179 |
| Free Cash Flow | -11,442 | -41,377 | -27,695 | -19,746 | -9,410 |